Notably, the distribution of CFH haplotypes in the recall study cohort had a more pronounced effect than AMD case-control status, which may be an important learning for the design of future such studies that for participant selection might want to take into account more granular phenotypes than the widely defined AMD code we relied on in our study. The gene discussed is CFH; the disease is age-related macular degeneration.